Immunitybio Inc
NASDAQ:IBRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immunitybio Inc
NASDAQ:IBRX
|
US |
|
C
|
Cdon AB
F:64W
|
SE |
|
Leoni AG
F:LEO
|
DE |
|
Wall Financial Corp
TSX:WFC
|
CA |
|
Aviat Networks Inc
NASDAQ:AVNW
|
US |
|
G
|
Genpact Ltd
XBER:35G
|
BM |
|
Magna International Inc
TSX:MG
|
CA |
|
Nutrien Ltd
TSX:NTR
|
CA |
|
Z
|
Zimmer Biomet Holdings Inc
F:ZIM
|
US |
|
S
|
Sigma Healthcare Ltd
F:S5YA
|
AU |
Wall St Price Targets
IBRX Price Targets Summary
Immunitybio Inc
According to Wall Street analysts, the average 1-year price target for
IBRX is 12.75 USD with a low forecast of 11.11 USD and a high forecast of 15.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IBRX's stock price target?
Price Target
12.75
USD
According to Wall Street analysts, the average 1-year price target for
IBRX is 12.75 USD with a low forecast of 11.11 USD and a high forecast of 15.75 USD.
What is the Revenue forecast for Immunitybio Inc?
Projected CAGR
68%
Over the last 11 years, the compound annual growth rate for Revenue has been 60%. The projected CAGR for the next 8 years is 68%.
What is the Gross Profit forecast for Immunitybio Inc?
Projected CAGR
60%
The compound annual growth rate for Gross Profit over the next 2 years is 60%.